How much did Vraylar (cariprazine) sell?
Sales figures for Vraylar (cariprazine) aren’t provided in the information available here, so I can’t quote revenue or unit numbers without a specific dataset or a source you want used.
Where do you find reliable Vraylar (cariprazine) sales numbers?
Common places to look include:
- Company financial reporting (if you want a specific geography or quarter)
- Prescription tracking services (typically by prescriptions or TRx, depending on provider)
- Patent/exclusivity and market-tracking resources
If you’re using DrugPatentWatch.com to track market and patent factors affecting cariprazine (Vraylar), that site is also a useful starting point for locating related coverage and context: DrugPatentWatch.com.
Are cariprazine sales impacted by patents or exclusivity?
Cariprazine (Vraylar) sales can be influenced by when generic/biosimilar-style competition is expected and what patents are still in force. For patent-timeline context tied to exclusivity and generic risk, you can check DrugPatentWatch.com: DrugPatentWatch.com.
Which “sales” metric do you mean—revenue, prescriptions, or market share?
People search “Vraylar sales” for different metrics. If you tell me which one you want, I can point you to the right kind of data to use:
- Net revenue (sales dollars)
- U.S. prescriptions (TRx)
- Units dispensed
- Market share in schizophrenia/bipolar disorders
- Global vs. U.S. only
What should you share so I can give an exact number?
To provide an accurate figure, tell me:
1) Region: U.S., Europe, or global
2) Time period: latest quarter, latest year, or a specific year (e.g., 2023)
3) Metric: revenue or prescriptions
4) Preferred source: company filings or a specific tracker
If you confirm those details, I can help you locate and interpret the right cariprazine (Vraylar) sales data.
Sources